Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study

INTRODUCTION/PURPOSE: Relacorilant is a selective glucocorticoid receptor modulator (SGRM) with no progesterone receptor activity. We evaluated the efficacy and safety of relacorilant in patients with endogenous Cushing syndrome (CS). MATERIALS AND METHODS: A single-arm, open-label, phase 2, dose-fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Pivonello, Rosario, Bancos, Irina, Feelders, Richard A., Kargi, Atil Y., Kerr, Janice M., Gordon, Murray B., Mariash, Cary N., Terzolo, Massimo, Ellison, Noel, Moraitis, Andreas G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317576/
https://www.ncbi.nlm.nih.gov/pubmed/34335465
http://dx.doi.org/10.3389/fendo.2021.662865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317576/
https://www.ncbi.nlm.nih.gov/pubmed/34335465
http://dx.doi.org/10.3389/fendo.2021.662865

Ejemplares similares